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High-dose hypofractionated radiotherapy is effective and safe
for tumors in the head-and-neck
Sewit Teckie, MD1,3,*, Benjamin H. Lok, MD1, Shyam Rao, MD, PhD1,4, Stanley I. Gutiontov,
BS1,5, Yoshiya Yamada, MD1, Sean L. Berry, PhD2, Michael J. Zelefsky, MD1, and Nancy Y.
Lee, MD1
1Department
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of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue,
New York, NY, 10065
2Department

of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue,
New York, NY, 10065

Abstract
Objectives—High-dose, hypofractionated radiotherapy (HFRT) is sometimes used to treat
malignancy in the head-and-neck (HN), both in the curative and palliative setting. Its safety and
efficacy have been reported in small studies and are still controversial.
Materials and Methods—We retrospectively evaluated the outcomes and toxicities of HFRT,
including ultra-high-dose fractionation schemes (≥8 Gray per fraction), for HN malignancies.
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Results—A total of 62 sites of measurable gross disease in 48 patients were analyzed. The
median follow-up was 54.3 months among five survivors and 6.0 months in the remaining patients.
Median RT dose was 30 Gray in 5 fractions; 20/62 lesions (32%) received dose-per-fraction of ≥8
Gray. Overall response rate at first follow-up was 79%. One-year local-progression free rate was
50%. On multivariate analysis for locoregional control, dose-per-fraction ≥6 Gray was associated
with control (p=0.04) and previous radiation was associated with inferior control (p= 0.04).
Patients who achieved complete response to RT had longer survival than those who did not
(p=0.01). Increased toxicity rates were not observed among patients treated with dose-per-fraction
≥8 Gray; only re-irradiation increased toxicity rates.
Conclusion—Despite the poor prognostic features noted in this cohort of patients with HN
malignancies, HFRT was associated with high response rates, good local control, and acceptable
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toxicity. Sites that were treated with 6 Gray per fraction or higher and had not been previously
irradiated had the best disease control. A prospective trial is warranted to further refine the use and
indications of HFRT in this setting.

INTRODUCTION

Author Manuscript

Hypofractionated radiation therapy (HFRT) involves the use of high doses per fraction to
achieve improved tumor control. A more desirable therapeutic ratio has been achieved for
HFRT in recent years through the use of image-guided RT (IGRT), which allows improved
certainty regarding daily treatment setup and dose delivered to organs at risk. IGRT has in
turn facilitated the use of stereotactic body radiation therapy (SBRT), which allows delivery
of highly conformal, high doses of radiotherapy to a clinical target. Preclinical data show
that high-dose single-fraction RT operates via a unique mechanism involving injury of tumor
endothelial cells that is distinct from conventionally fractionated RT and independent of
tumor histologic subtype.[1] Clinical data show that HFRT improves local tumor control
beyond that possible using conventional fractionation, for various scenarios including earlystage lung cancer,[2, 3] radioresistant histologies such as melanoma and renal cell cancers,
[4–7] and oligometastatic disease.[8–12]
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In recent years, a growing body of literature has reported on the safety and feasibility of
HFRT for tumors of the head and neck (HN).[13–20] Most of these series include patients
with recurrent, unresectable HN cancers who had been previously irradiated. These studies
have found promising overall response rates up to 80% and 1-year local control rates in the
range of 50%. Despite promising tumor control, severe toxicities have occurred in patients
receiving HFRT for re-irradiation, including carotid blowout and hemorrhage.[14, 19]
Carotid blowout in particular is a severe complication of high-dose radiation therapy in
which there is physical rupture of the carotid artery and hemorrhage. This hemorrhage is
potentially fatal if not addressed emergently. Several groups have reported on outcomes of
HFRT used to treat a heterogeneous group of HN malignancies, including primary,
recurrent, and metastatic tumors.[20, 21] These studies have also shown high response rates
and 2-year local control rates of 30% to 40%, with limited toxicity in patients who had not
been previously irradiated.
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In our institution, HFRT is routinely offered to the most challenging HN disease
presentations: those with “radioresistant” histologies (such as melanoma and renal cell
carcinoma), cases of disease recurrence in a previously irradiated field, or bulky lesions for
which rapid palliation is desired. After the year 2004, IGRT became available in our center.
In recent years, SBRT has been routinely used for treatment of lesions with proximity to
critical structures. As we have gained experience with HFRT in HN cancers, our dose
prescribed per fraction has increased over time. In this study, we report on the outcomes and
toxicity of HFRT for various malignancies with measurable gross disease in the HN. We also
analyze the outcomes of patients who received an ultra-high dose (≥8 Gray per fraction)
hypofractionated regimen to determine if these more intensive regimens were associated
with improved outcomes.
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MATERIAL AND METHODS
We reviewed all cases of hypofractionated HN RT, which we defined as a dose of 5Gy or
more per fraction, treated at our center from January 1997 to July 2014. We excluded
patients who did not complete the prescribed course of radiotherapy and those who were
treated to bone-only sites including the clivus. We therefore identified a total of 123 patients
treated to 163 lesions in the HN. Within this group, we limited our analysis to patients with
measurable gross disease, thereby excluding postoperative treatments following gross total
resections, and at least one follow-up visit 30 days or more after completing HFRT.

Author Manuscript
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Patients were offered HFRT to the HN tumor if they had one or both of the following
features, as determined by the attending radiation oncologist: 1) radioresistant histology that
would benefit from higher doses per fraction, 2) prior RT at the same site and not a
candidate for salvage surgical resection or conventionally fractionated external beam RT, or
3) no prior RT at the site, but cannot tolerate surgical resection or conventionally
fractionated RT to curative doses. Patients were treated with either “definitive” or
“palliative” intent. Patients treated “definitively” did not have evidence of metastatic disease
and were technically considered “curable” despite being ineligible for surgical or other
modalities of treatment. Patients treated with “palliative” intent had other metastatic or
locoregional disease and were considered “incurable” even if this course of RT were to lead
to a complete response of the treated lesion. Pretreatment evaluation consisted of a complete
history and physical examination, comprehensive metabolic panel, complete blood count,
computed tomography (CT) of the HN and chest, magnetic resonance imaging (MRI) as
indicated, and whole body positron-emission tomography (PET) as indicated. Our
institutional review board approved a waiver of written informed consent for this
retrospective study.
Radiation treatment design
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All patients underwent either CT or PET-CT simulation. CT images were obtained using 2–3
mm slice thickness. Patients were immobilized in either a three-point or five-point
thermoplastic face mask. Intravenous contrast was used for the simulation scan when
indicated. Following CT-simulation, target volume was defined using available diagnostic
CT, MRI, and/or PET images alongside the planning scan. For patients undergoing PET-CT
simulation, the target volume was defined using the hypermetabolic tumor volume on the
fused PET-CT scan. Treatments were targeted to local disease without elective nodal
treatment. Any clinically or radiographically measurable gross disease was defined as the
gross tumor volume (GTV). CTV was typically a 3–10 mm three-dimensional expansion on
the GTV. The planning target volume (PTV) expansion on the CTV was dependent on the
alignment technique, but was typically 2–3 mm for cases receiving IGRT with kV planar
imaging or cone beam CT.
Dose was generally fractionated and delivered daily or every other day. Total dose and
fractionation was selected by the attending radiation oncologist, based on field size, tumor
location, prior radiation dose, and patient functional status. Treatment planning for 3Dconformal and IMRT treatments was performed using our in-house treatment-planning
system. Dose was prescribed to the isodose line best covering the PTV, while also protecting
Oral Oncol. Author manuscript; available in PMC 2017 September 01.
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normal tissues. The permitted normal tissue doses were defined by the attending radiation
oncologist and were a function of fractionation scheme and any prior RT to the HN.
Response assessment
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We determined objective response to HFRT using both clinical assessment and follow-up
imaging. Patients were followed every 1–3 months on an outpatient basis. Follow-up
evaluation consisted of an interval history and clinical examination focusing on the HN,
often with fiberoptic endoscopy. Imaging included CT, MRI, and/or PET/CT routinely
performed on a 3 to 6 month schedule. The follow-up interval was calculated from the last
date of RT. Response was characterized using the RECIST criteria [22]: complete response
(CR) if all tumor disappeared on follow-up evaluation, partial response (PR) if tumor
exhibited at least >30% decrease in sum of diameters, stable disease (SD) if there was no
change in tumor volume, and progression of disease (PD) if there was any increase in tumor
size >20% and >5mm relative to pre-RT tumor volume. In certain cases progression was
determined by the treating physician using primarily clinical examination.
Statistical analysis
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We calculated in-field progression rate, locoregional progression-free rate (LRPF), overall
survival (OS), and toxicity. All events were indexed to the final date of RT treatment. Infield progression was defined as failure within the treatment field, and locoregional
progression was defined as progression either in the treatment field or in a regional lymph
node group or neighboring site. OS was calculated from the date of completion of the initial
course of HFRT, to the date of death. Patients without events were censored at last followup. Complications were scored per the Common Terminology Criteria for Adverse Events,
version 4 (CTCAEv.4).[23] The Kaplan-Meier method was used for the generation of
survival curves, and differences in survival curves were compared statistically with the logrank test. Univariate and multivariate analyses of potential prognostic factors were
performed using the Cox proportional hazards model. The chi-square test was used to
compare rates between subgroups of patients. All provided p values are two-sided with an αlevel of 0.05 considered significant. All statistical analysis was accomplished with the SPSS
software package, version 22 (IBM, Armonk, NY).

RESULTS
Patient characteristics

Author Manuscript

Baseline characteristics for the initial cohort of 163 lesions in 123 patients, as well as for the
analyzed group of 48 patients with 62 lesions, are available in Table 1. Predominant
histologies of the 62 HN lesions were cutaneous melanoma (19%), mucosal melanoma
(18%), squamous cell carcinoma (10%), and sarcomas (11%). Primary tumor site was nasal
cavity in 18%, skin in 18%, and non-skin, metastatic cancer originating outside of the HN in
23%. The HN had been previously irradiated in 24% of cases.
Treatment characteristics
Details of treatment, including sites and doses prescribed, are summarized in Table 2.
Median age at HFRT was 70.2 years (range, 34–95). Patients were treated to a variety of HN
Oral Oncol. Author manuscript; available in PMC 2017 September 01.
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sites, with the neck (36%) being the most common. Treatment intent was definitive in 52%,
and palliative in 48%. Median prescribed dose was 30 Gy (range, 18–48) in 5 fractions
(range, 1–6). When dose was converted into equivalent dose in 2-Gy fractions (EQD2)[23]
using an α/β ratio of 3 for radioresistant histologies (melanoma and renal cell carcinoma)
and an α/β ratio of 10 for other histologies, median EQD2 was 50 Gy (range, 24–108).
Dose per fraction of 8 Gy or more was used in 20 (33%) cases. Three patients were treated
with 5 Gy per fraction to a total dose of 25 Gy. The majority of patients (92%) were treated
with intensity-modulated radiotherapy (IMRT) or 3D conformal RT. IGRT with on-board 2D
or 3D techniques was used in 56% of patients, all treated in 2007 or later. All patients with
melanoma or renal cell carcinoma (n=26) received HFRT with EQD2 ≥50 Gy. Patients with
melanoma and renal cell carcinoma histologies were significantly more likely to receive an
EQD2 ≥50 Gy than patients with other histologies (p ≤ 0.001).
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Response to Treatment and Recurrences
Among the 48 patients with 62 treated lesions, median follow-up was 54.3 months among
five surviving patients and 6.0 months in remaining patients. Response to RT is outlined in
Table 3. At first follow-up visit after RT, 79% of target lesions demonstrated response, 16%
had stable disease, and 3% had progression of disease. The two patients with progressive
disease had anaplastic thyroid cancer metastatic to the orbit, and cutaneous squamous cell
carcinoma metastatic to the parotid gland.
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Among the 59 cases with either disease response or stability following HFRT, 10 cases
remained progression-free, in both locoregional and distant sites. The most common site of
relapse was distant-only in 34% of cases. Isolated locoregional failure in the HN without
distant relapse occurred in 23 cases (39%), including 12 (19%) with isolated in-field
recurrence without any regional or distant failure. In patients who recurred, median times to
both isolated in-field progression and isolated LRP was 6.2 months (range, 0 – 33.9).
Overall Survival
Median OS for all 48 patients was 7.2 months (95% Confidence Interval [CI] 5.6 – 8.8
months) [Figure 1a]. On log-rank testing, patients with complete response to treatment had
far superior OS to those with less than complete response: 1-year OS was 100%, vs 34% in
partial-response group (p=0.03) [Figure 1b]. Patients with metastatic tumors that had
traveled to the head-and-neck also had inferior OS (median 6.5 vs 9.4 months, p= 0.05)
[Figure 1c]. No difference in OS was observed based on dose per fraction ≥6 Gy or ≥8 Gy,
age, chemotherapy use, EQD2, re-irradiation, or histology.
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Five patients out of 48 were alive at last follow-up. In 43 patients who died, cause was headand-neck disease in 13 patients and due to other cause including systemic disease in 30
cases.
Locoregional progression-free rate
LRPF rates were 70% (95% CI 57–83%) at 6-months, 43% (95% CI 27–59%) at 12-months,
and 29% (95% CI 13–45%) at 2-years. On log-rank test, lesions with complete response
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after HFRT had superior LRPF than patients with initial PR or less response (1-year rate
67% if CR vs 42% if PR, p=0.009). Dose-per-fraction ≥6 Gy was associated with improved
LRPF (1-year rate 46% vs 0%, p=0.01); dose-per-fraction ≥8 Gy was also significantly
associated with improved LRPF (1-year rate 73% vs 34%, p=0.038) [Figures 2b and 2c].
Patients receiving re-irradiation had worse LRPF (median LRPF 12.7 months vs 6.2 months,
p=0.017), which may be attributed to the lower dose per fraction and smaller radiation field
treated in patients receiving re-irradiation. No significant differences in LRPF were observed
based on tumor histology, receipt of chemotherapy, PTV volume, metastatic vs. primary HN
tumor, or EQD2.
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A subgroup analysis was performed on the 46 patients who had both 1) not received
previous radiation, and 2) were treated with dose-per-fraction of 600cGy or higher. LRPF
rates were 78% (95% CI 63–93%) at 6-months, 56% (95% CI 34–77%) at 12 months, and
45% (95% CI 22 – 67%) at 2-years. Dose-per-fraction of 8Gy or higher was marginally
associated with improved LRPF, although not statistically significant (1-year rate 83% vs
45%, p=0.127). Other factors tested were not associated with differences in LRPF.
In-field control
Median in-field control was 11.9 months, with a 6-month estimate of 81% (95% CI 6893%). Dose-per-fraction ≥6 Gy was associated with improved in-field control (12-month
rate 54% vs 0%, p<0.001). No significant difference was seen among patients receiving 8Gy
or higher (p=0.18). In-field control was not significantly worse in patients receiving reirradiation (12-month rate 60% vs 30%, p=0.10). No significant differences in in-field
control were observed based on EQD2, chemotherapy, PTV volume, tumor histology, and
metastatic vs. primary HN tumor.
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A subgroup analysis was again performed on the 46 patients without re-irradiation, and with
dose-per-fraction of 600cGy or higher. Median in-field control was 33.8 months, with a 6month estimate of 86% (95% CI 72 – 99%). No significant difference in in-field control was
seen among patients based on dose 8Gy or higher (p=0.12), EQD2, chemotherapy, PTV
volume, tumor histology, and metastatic vs primary HN tumor.
Cox Regression Analyses
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Factors with p-value <0.10 on log-rank analysis for in-field control (Dose ≥6 Gy, reirradiation) and LRPF (Dose ≥6 Gy, dose ≥8 Gy, re-irradiation) were included in univariate
and multivariate Cox regression analysis. For in-field control, only dose-per-fraction ≥6 Gy
(HR, 0.1; p = 0.004; 95% CI, 0.02 – 0.42) remained significant. For LRPF, re-irradiation
(HR, 2.2; p = 0.036; 95% CI, 1.1 – 4.5) and dose-per-fraction ≥6 Gy retained significance
(HR, 0.27; p = 0.04; 95% CI, 0.08 – 0.95).
Toxicity
The highest acute toxicity that occurred was grade 1 in 37 cases (60%), grade 2 in 6%, and
grade 3 in one case. No acute grade 4 or 5 toxicities occurred. Late grade 2 toxicities were
recorded in 13% of cases, and 3% percent experienced late grade 3 complications, both
involving retinopathies and vision loss. No carotid blowout or hemorrhage developed
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following HFRT. On Chi-square test, sites that were re-irradiated were significantly more
likely to experience grade ≥2 late toxicity (p <0.001) but not grade ≥2 acute toxicity. Dose
≥8 Gy per fraction was not associated with an increase in grade ≥2 acute or late toxicities.
No increased grade ≥2 late toxicity was seen in patients treated before routine use of onboard imaging in 2004.

DISCUSSION

Author Manuscript

Locoregional control of malignancies in the head-and-neck is of paramount importance for
quality of life and survival. Uncontrolled HN disease progression causes significant
morbidity, justifying a more aggressive approach for recurrent disease or palliation of
metastatic disease. In the setting of HN disease that cannot be surgically resected, the use of
IGRT and SBRT has paved the way for radiotherapy dose-escalation, thereby improving the
therapeutic ratio and locoregional disease control. Unfortunately, and especially for recurrent
HN disease, RT comes with a risk of severe toxicities.[24–30] Hypofractionated IGRT with
doses of 4–10 Gy per fraction has been used extensively in non-HN tumor sites and is
considered a safe and effective treatment, particularly for radioresistant histologies and
previously irradiated disease.[31, 32] Preclinical and clinical data show that higher doses per
fraction overcome the traditional radioresistance of certain histologies.[4, 6, 7] HFRT
represents an attractive treatment option for unresectable disease, because of an increase in
local control over conventionally fractionated RT.[4] Another advantage of HFRT in the
palliative setting is the shorter overall treatment time, which minimizes disruption of
important systemic therapies. A small body of literature has described the use of HFRT for
heterogeneous tumors in the HN, but more widespread application in the HN has yet to
occur.
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In our study, we find that patients who achieve CR to treatment have not only improved
locoregional disease control, but also improved overall survival. Our finding underscores the
great importance of local control for HN cancers. We also find that the dose-per-fraction of
6Gy or higher with a median of 5 fractions is associated with improved outcomes compared
to lower dose/fractionation schemes. In our study, patients who were re-irradiated had
uniformly worse outcomes. These patients may benefit from a more aggressive
multidisciplinary approach involving maximal resection, re-RT, and systemic therapy. For
those who cannot undergo resection, a growing body of evidence shows that dose-escalated
HFRT using SBRT to 40Gy or higher is associated with improved local control [15, 16, 21].
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Our study also adds to the HN HFRT literature by including 20 patients treated with a dose
per fraction of 8 Gy or above. On log-rank testing and univariate analysis, this dose range is
associated with a trend to improved local control, although the analysis is limited by small
patient numbers and low life-expectancy of this highly unfavorable patient population. With
the rapid advances in SBRT planning and delivery, we can now safely treat gross tumor
burden in the HN with doses that provide optimal local control. Our sample size is small and
longer follow-up may reveal late toxicities; our results are nevertheless promising. We are in
the process of generating a prospective trial of hypofractionated RT using SBRT for tumors
in the HN, with the aims of evaluating toxicity, efficacy, and potentially broadening the
indications for these treatments.
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Several series have found severe toxicities associated with SBRT for reirradiation of HN
tumors. Cengiz et al[14] treated 46 patients with recurrent previously irradiated HN cancers
to a median dose of 30 Gy in 5 fractions and found that 17% of patients had carotid blowout
and 15% died of carotid bleeding. These patients had recurrent disease involving the carotid
artery, which received full prescription dose. A Korean group treated 36 patients with
previously irradiated HNC to doses of 18–40 Gy in 3–5 fractions; 3 developed necrosis
associated with treatment.[13] A group from Kyoto[19] treated 21 recurrent HN cancers
with CyberKnife SBRT to a median dose of 30 Gy in 3–8 fractions. At 24 months, OS was
50%, but two patients died of pharyngeal hemorrhage at 5 and 28 months. The Henry Ford
Hospital group[21] treated 37 HN lesions with fractionated SBRT of 36–48 Gy in 5–8
fractions, and 18 lesions with single-fraction SBRT. They achieved 1-year tumor control
rates of 61% to 83% and reported three grade 3 and four grade 4 toxicities, including fistulae
that resulted from disease progression or regression. Unger et al[33] treated 65 patients with
previously irradiated HN lesions to a median SBRT dose of 30 Gy in 5 fractions. Response
was achieved in 81%. Severe toxicity including arterial bleeding, neuropathy, trismus,
dysphagia, and necrosis developed in 11% of patients.

Author Manuscript

Other groups have achieved high response rates with acceptable toxicities. The University of
Michigan published one of the earliest reports of HN SBRT[17] in which 13 patients were
treated with SBRT to doses of 12–18 Gy in a single fraction or 30 Gy in 5–6 fractions. At 6months, nine patients showed response and no patients had acute or subacute radiation
toxicity. The Pittsburgh experience[15] with CyberKnife for recurrent HN squamous cell
carcinoma included 22 patients treated to a median dose of 24 Gy in 1–8 fractions. They
report only two grade 2–3 acute toxicities and no late toxicities at a median follow-up of 19
months. The same group reported results of SBRT reirradiation to the HN in 85 patients[16]:
at 2 years, local control was 31% and OS was 16%. They found only four grade 3 acute
toxicities, and no grade 3 or greater late toxicities. Comet et al[18] treated 43 previously
irradiated HN lesions to 36 Gy in 6 fractions. At a median follow-up of almost 26 months,
79% of patients achieved response and four patients had grade 3 toxicity. The authors note
that they did not treat tumors invading more than one-third of the carotid artery.
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Controversies do exist regarding the appropriateness of the linear-quadratic model in the
setting of high-dose radiotherapy and radiosurgery.[35, 36] Studies of single-fraction
radiosurgery show that cell killing at dose levels above 10 Gy occurs partially as a
consequence of vascular endothelial damage, in addition to the classical model of singleand double-strand DNA breaks [1, 6]. The LQ model therefore underestimates the biological
effects of a single-fraction dose that is “biologically equivalent” to a conventionally
fractionated course, with equivalence calculated using the EQD2 model.[35] Several groups
have proposed LQ models that better fit the observed in vitro cell kill from higher doses per
fraction of radiosurgery[36], but these models are not yet widely accepted for clinical use.
We currently do not have another reliably validated model to help us compare conventional
fractionation and high-dose hypofractionation. We therefore used the LQ model and
EQD-2Gy in order to facilitate comparison between the hypofractionated doses used in our
study and a “biologically equivalent” conventionally fractionated course.

Oral Oncol. Author manuscript; available in PMC 2017 September 01.

Teckie et al.

Page 9

Author Manuscript

Several potential sources of bias exist in this retrospective study. First, the decision to use
HFRT versus conventional RT was chosen by the individual treating physician and not
according to any formal criteria. We did find that patients with radioresistant histologies
were more likely to receive a higher EQD2, a finding that is consistent with clinical practice.
Another limitation of our study is the short survival and short median follow-up of patients
who died, which may underestimate the number of late toxicities we encounter. However,
with a median overall survival of 7.2 months, our length of follow-up is appropriate for this
patient population with poor overall prognosis.
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Our study shows that hypofractionated RT can be delivered safely and provides relatively
high local control for challenging cancers in the HN and that a higher dose-per-fraction is
associated with improved in-field control. More stringent selection criteria for HFRT,
combined with more tailoring of dose and fractionation schedules to the individual lesion
and patient, can likely reduce the development of late severe toxicities. A prospective doseescalation trial is warranted to find the optimal dose scheme in these patients.
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Highlights
1.

Hypofractionated head and neck radiation therapy is controversial due to
toxicity concerns.

2.

62 sites of measurable head-and-neck tumors were treated with high-dose
radiation therapy.

3.

Dose per fraction of 6Gy or greater had improved locoregional control.

4.

Re-irradiated patients had worse disease control after hypofractionated
radiation.

5.

No increased toxicity was seen in patients treated with higher doses per
fraction.
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Figure 1.

Figure 1a. Overall Survival.

Oral Oncol. Author manuscript; available in PMC 2017 September 01.

Teckie et al.

Page 14

Author Manuscript

Figure 1b. Overall survival stratified by response to radiation therapy.
Figure 1c. Overall survival stratified by primary site of tumor (metastatic vs H&N).
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Figure 2.
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Figure 2a. Locoregional Progression-Free Survival.
Figure 2b. Locoregional progression-free rate, stratified by dose-per-fraction of 6Gy or
higher.
Figure 2c. Locoregional progression-free rate, stratified by dose-per-fraction of 8Gy or
higher.

Author Manuscript
Oral Oncol. Author manuscript; available in PMC 2017 September 01.

Teckie et al.

Page 17

TABLE 1

Author Manuscript

Pretreatment clinical characteristics.
Characteristic

Entire cohort (n=163), N (%)

Intact tumors (n=62), N (%)

67.6 (18–95)

70.2 (34–95)

Skin

68 (42)

11 (18)

Nasal cavity

30 (18)

11 (18)

Metastatic, non-skin cancer

Age, years (median, range)

Primary tumor location

Author Manuscript

20 (12)

14 (23)

Oral cavity

9 (6)

2 (3)

Paranasal sinus

7 (4)

4 (6)

Neck

7 (4)

3 (5)

Thyroid

6 (4)

6 (10)

Parotid

4 (2)

4 (6)

Nasopharynx

3 (2)

2 (3)

Orbit

2 (1)

0 (0)

Masticator space

2 (1)

2 (3)

Oropharynx

1 (0.6)

0 (0)

Hypopharynx

1 (0.6)

0 (0)

Larynx

1 (0.6)

1 (2)

Salivary Gland

1 (0.6)

1 (2)

Unknown primary

1 (0.6)

1 (2)

Cutaneous melanoma

73 (45)

12 (19)

Mucosal melanoma

38 (23)

11 (18)

Squamous cell carcinoma

11 (6)

6 (10)

Sarcomas

10 (6)

7 (11)

Carcinoma, NOS

7 (4)

6 (10)

Thyroid

6 (4)

6 (10)

Renal cell carcinoma

6 (4)

3 (5)

Adenoid cystic

3 (2)

3 (5)

Esthesioneuroblastoma

3 (2)

3 (5)

Neuroendocrine

2 (1)

2 (3)

Salivary gland carcinoma

2 (1)

2 (3)

Histologic diagnosis

Author Manuscript

Non-small cell lung cancer
Prior head and neck RT

2 (1)

1 (2)

18 (11)

18 (24)

Abbreviation: RT, radiotherapy; NOS, not otherwise specified.
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Details of head and neck sites treated with HFRT.
Characteristic

Entire cohort (n=163), N (%)

Intact tumors (n=62), N (%)

Neck

55 (34)

22 (36)

Sinonasal

34 (21)

9 (15)

Skin

29 (18)

10 (16)

Parotid

Treated Sites

16 (10)

6 (10)

Orbit

7 (4)

6 (10)

Mandible

5 (3)

3 (5)

Ear

4 (2)

2 (3)

Oral cavity

4 (2)

0 (0)

Nasopharynx

3 (2)

2 (3)

Author Manuscript

Oropharynx

3 (2)

0 (0)

Hypopharynx

1 (0.6)

1 (2)

Maxilla

1 (0.6)

0 (0)

Thyroid

1 (0.6)

1 (2)

PTV Treated, cc, median (range)

112 (8 – 606cc)

Peri-radiotherapy chemotherapy
None

32 (52)

Yes, Before RT only

9 (15)

Yes, Before, During, After RT

8 (13)

Yes, After RT only

3 (5)

Yes, Before and After RT only
Months received, median (range)

9 (15)
6.1 (1.8 – 11.4)

Author Manuscript

RT Doses Received
30Gy in 5 fx (6Gy per fx)

27 (44)

36Gy in 6 fx (6Gy per fx)

11 (18)

30Gy in 3 fx (10Gy per fx)

10 (16)

24Gy in 3 fx (8Gy per fx)

4 (6)

25Gy in 3 fx (5Gy per fx)

3 (5)

27Gy in 3 fx (9Gy per fx)

2 (3)

36Gy in 3 fx (12Gy per fx)

1 (2)

48Gy in 4 fx (12Gy per fx)

1 (2)

24Gy in 1 fx (24Gy per fx)

1 (2)

20Gy in 2 fx (10Gy per fx)

1 (2)

18Gy in 3 fx (6Gy per fx)

1 (2)
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Abbreviations: HFRT, hypofractionated radiotherapy. RT, radiation therapy. Gy, Gray. Fx, fractions. PTV, planning target volumes.
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Initial responses to head and neck HFRT (n=62).
Characteristic

N (%)

Response
Complete

6 (10)

Partial

43 (69)

Stable disease

10 (16)

Progressive disease

2 (3)

Unknown

1 (2)

Modality to determine response
CT

10 (16)

PET/CT

10 (16)

MRI

16 (26)
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CT and MRI

2 (3)

Clinical examination only

24 (39)

Abbreviations: CT, computed tomography. PET, postiron emission tomography. MRI, magnetic resonance imaging.
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Sites of first recurrence in 59 treated lesions who initially had response or stable disease.
Location

N (%)

Local (in-field) only

12 (19)

Regional only

9 (15)

Distant only

21 (34)

Local and regional

4 (6)

Local and distant

1 (2)

Regional and distant

3 (5)

Local, regional, and distant
No recurrence

1 (2)
11 (18)
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